PMID- 37303737
OWN - NLM
STAT- MEDLINE
DCOM- 20230613
LR  - 20230613
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 31
IP  - 1
DP  - 2023
TI  - H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus.
PG  - 23-34
LID - 10.32604/or.2022.028449 [doi]
AB  - This study aimed to examine the association between the use of H1-antihistamines 
      (AHs) and head and neck cancer (HNC) risk in patients with type 2 diabetes 
      mellitus (T2DM). Data from the National Health Insurance Research Database of 
      Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched 
      cohort of 54,384 patients each in the AH user and nonuser groups was created and 
      analyzed using Kaplan-Meier method and Cox proportional hazards regression. The 
      results showed that the risk of HNC was significantly lower in AH users (adjusted 
      hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower 
      (5.16 vs. 8.10 per 100,000 person-years). The lower HNC incidence rate in AH 
      users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may reduce the risk of 
      HNC in T2DM patients.
CI  - (c) 2023 Chen et al.
FAU - Chen, Yi-Nong
AU  - Chen YN
AD  - Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai 
      Hospital, Yilan, Taiwan.
FAU - Chen, Ying-Lin
AU  - Chen YL
AD  - Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai 
      Hospital, Yilan, Taiwan.
FAU - Chen, Wan-Ming
AU  - Chen WM
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
FAU - Chen, Mingchih
AU  - Chen M
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
FAU - Shia, Ben-Chang
AU  - Shia BC
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
FAU - Ko, Jenq-Yuh
AU  - Ko JY
AD  - Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai 
      Hospital, Yilan, Taiwan.
AD  - Department of Otolaryngology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, Taipei, Taiwan.
FAU - Wu, Szu-Yuan
AU  - Wu SY
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
AD  - Department of Food Nutrition and Health Biotechnology, College of Medical and 
      Health Science, Asia University, Taichung, Taiwan.
AD  - Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai 
      Hospital, Yilan, Taiwan.
AD  - Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, 
      Taiwan.
AD  - Department of Healthcare Administration, College of Medical and Health Science, 
      Asia University, Taichung, Taiwan.
AD  - Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
AD  - Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang 
      Hospital, Taipei Medical University, Taipei, Taiwan.
AD  - Department of Management, College of Management, Fo Guang University, Yilan, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20230301
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - 0 (Histamine Antagonists)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Head and Neck Neoplasms/epidemiology
MH  - Histamine Antagonists
PMC - PMC10208039
OTO - NOTNLM
OT  - H1-Antihistamine
OT  - Head and neck cancer
OT  - Incidence
OT  - Incidence rate
OT  - Type 2 diabetes
COIS- The authors declare that they have no conflicts of interest to report regarding 
      the present study.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/13 06:42
PMCR- 2023/03/01
CRDT- 2023/06/12 03:57
PHST- 2022/12/18 00:00 [received]
PHST- 2023/02/02 00:00 [accepted]
PHST- 2023/06/13 06:42 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 03:57 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 28449 [pii]
AID - 10.32604/or.2022.028449 [doi]
PST - epublish
SO  - Oncol Res. 2023 Mar 1;31(1):23-34. doi: 10.32604/or.2022.028449. eCollection 
      2023.